MoF against market-based drug pricing
Abantika Ghosh: New Delhi, Nov 08 2012, 03:01 IST
of data that would be required on an annual basis to implement a cost-based pricing system is perceived by the industry as intrusive and hence, vehemently opposed.
Moreover, cost-based pricing limits the scope of entry of new players, leading to stagnation of production activity, competition, and may eventually have serious implications for the availability of NLEM medicines.
Previous Story Jubilant FoodWorks net up 37%; will continue to expand Next Story Bharti Airtel net dips 5.38% at Rs.721 crore
Reader's Comments| Post a Comment
Be the first to comment.
